PRediction of acute coronary syndrome in acute ischemic StrokE (PRAISE) – protocol of a prospective, multicenter trial with central reading and predefined endpoints

BMC Neurology

David M. Leistner¹  Ulf Landmesser¹  Vera Regitz-Zagrosek²  Burkert Pieske²  Andreas M. Zeiher²  Stephan Blankenberg²  Hugo Katus²  Martin Dichgans³  Gabor C. Petzold³  Karl Wegscheider⁴  Jan F. Scheitz⁵  Simon Litmeier⁵  Christian H. Nolte⁵  Matthias Endres⁵  Regina von Rennenberg⁵ 

[1] Berlin Institute of Health (BiH);Deutsches Zentrum für Herz-Kreislauf-Forschung e.V. (DZHK);Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) – German Center for Neurodegenerative Diseases;Institut für Medizinische Biometrie und Epidemiologie, Universitätsklinikum Hamburg-Eppendorf;Klinik für Neurologie mit Experimentelle Neurologie, Charité-Universitätsmedizin Berlin;

关键词: Acute ischemic stroke;    Troponin elevation;    Acute coronary syndrome;    Heart-and-brain interaction;    Stroke-heart-syndrome;    Chronic coronary disease;   

DOI  :  10.1186/s12883-020-01903-0

来源: DOAJ

【 摘 要 】

Abstract Background Current guidelines recommend measurement of troponin in acute ischemic stroke (AIS) patients. In AIS patients, troponin elevation is associated with increased mortality and worse outcome. However, uncertainty remains regarding the underlying pathophysiology of troponin elevation after stroke, particularly regarding diagnostic and therapeutic consequences. Troponin elevation may be caused by coronary artery disease (CAD) and more precisely acute coronary syndrome (ACS). Both have a high prevalence in stroke patients and contribute to poor outcome. Therefore, better diagnostic algorithms are needed to identify those AIS patients likely to have ACS or other manifestations of CAD. Methods/design The primary goal of the “PRediction of Acute coronary syndrome in acute Ischemic StrokE” (PRAISE) study is to develop a diagnostic algorithm for prediction of ACS in AIS patients. The primary hypothesis will test whether dynamic high-sensitivity troponin levels determined by repeat measurements (i.e., “rise or fall-pattern”) indicate presence of ACS when compared to stable (chronic) troponin elevation. PRAISE is a prospective, multicenter, observational trial with central reading and predefined endpoints guided by a steering committee. Clinical symptoms, troponin levels as well as findings on electrocardiogram, echocardiogram, and coronary angiogram will be recorded and assessed by central academic core laboratories. Diagnosis of ACS will be made by an endpoint adjudication committee. Severe adverse events will be evaluated by a critical event committee. Safety will be judged by a data and safety monitoring board. Follow-up will be conducted at three and twelve months and will record new vascular events (i.e., stroke and myocardial infarction) as well as death, functional and cognitive status. According to sample size calculation, 251 patients have to be included. Discussion PRAISE will prospectively determine the frequency of ACS and characterize cardiac and coronary pathologies in a large, multicenter cohort of AIS patients with troponin elevation. The findings will elucidate the origin of troponin elevation, shed light on its impact on necessary diagnostic procedures and provide data on the safety and diagnostic yield of coronary angiography early after stroke. Thereby, PRAISE will help to refine algorithms and develop guidelines for the cardiac workup in AIS. Trial registration NCT03609385 registered 1st August 2018.

【 授权许可】

Unknown